Claims
- 1. A compound of the formula: wherein,X is —O—, —S—, —NH—, or —N(R2)—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, alkoxycarbonyl, and phenysulfonylphenylsulfonyl groups; aryl is as defined hereinafter; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino; R1 is —CR24R27—(CR23R24)n—CR24R27— wherein n is 0, 1, 2, or —CHR24—CH═CH—CHR24—, —CHR24—C≡C—CHR24—, —CHR24—CH═CH—CR23R24—CHR24—, —CHR24—CR23R24—CH═CH—CHR24—, —CHR24—C≡C—CR23R24—CHR24—, or —CHR24—CR23R24—C≡CHR24—, the —CH═CH— bond being cis or trans; R23 is hydrogen, (C1-C18)linear alkyl, phenyl, hydroxy, (C1-C18)alkoxy, aryloxy, aryl(C1-C18)alkyloxy, (C1-C18)alkanoyloxy, hydroxy(C1-C6)alkyl, (C1-C18)alkoxy(C1-C6)alkyl, phenyl(C1-C6)alkoxy, aryl(C1-C18)alkyloxy(C1-C6)alkyl, (C1-C18)alkanoyloxy(C1-C6)alkyl, or where Z1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2, or halogen, and p is as previously defined; andR24 is hydrogen, (C1-C18)linear alkyl, phenyl, hydroxy(C1-C6)alkyl, (C1-C18)alkoxy(C1-C6)alkyl, phenyl(C1-C6)alkyloxy, aryl(C1-C18)alkyloxy(C1-C6)alkyl, (C1-C18)alkanoyloxy(C1-C6)alkyl, or where Z1 is as previously defined, and p is as previously defined;R27 is hydrogen or R24 and R27 taken together with the carbon to which they are attached form C═O or C═S; and R18 and R19 are independently selected from the group consisting of: hydrogen, (C1-C18 straight or branched chain)alkyl, —C(═O)—O—(C1-C18)alkyl, —C(═O)—(C1-C18)alkyl, —C(—O—)-pyridyl—C(═O)-pyridyl,where NR18R19 taken together form a ring structure selected from the group consisting of piperidinyl, morpholinyl, and piperazinyl; where the piperidinyl or piperazinyl ring is optionally substituted by where X, Y, and Pp are as previously defined; whereR4 is hydrogen, lower alkyl, lower alkoxy, hydroxy, tri(C1-C6)alkylsilyloxy, hydroxy lower alkyl, alkanoyloxy lower alkyl, amino, mono- or dialkylamino, (C1-C18)acyl amino, (C1-C18)alkanoyl, trifluoromethyl, chlorine, fluorine, bromine, —O—C(═O)—(C1-C18) straight or branched chain)alkyl or —C(═O)-aryl; where R28 is hydrogen, (C1-C6) alkyl, aryl(C1-C6) alkyl, phenyl, or substituted phenyl; in which aryl is phenyl or wherein R5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C4-C18) carboxylicalkanoyl group, in addition, any nitrogen atom may alternatively bybe acylated with a (C4-C18)alkoxycarbonyl group; andm is 1, 2, or 3; with the proviso that when X is —O— and Y is hydrogen, lower alkyl, lower alkoxy, chlorine, fluorine, bromine, iodine, or a hydroxyl group, R18 and R19 are not lower alkyl; with the proviso that R18 and R19 are not hydrogen when R1 is (CH2)2-5—, X is —O—, and Y is 6-F;with the proviso that R23 is not hydrogen, (C1-C18)linear alkyl, phenyl, or when R27 is hydrogen and R24 is hydrogen, (C1-C18)linear alkyl, phenyl, or with the proviso that R24 is not hydrogen, (C1-C18)linear alkyl, phenyl, or when R27 is hydrogen and n is 0; or when R27 is hydrogen and R23 is hydrogen, (C1-C18)linear alkyl, phenyl, or or when R1 is —CHR24—CH═CH—CHR24— or —CHR24—C≡C—CHR24—; with the exception that the above provisos do not apply when R2 is alkoxycarbonyl; all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.
- 2. The compound of claim 1, wherein X is —N(R2)—.
- 3. The compound of claim 2, wherein R2 is (C1-C18)alkanoyl or (C1-C18)alkoxycarbonyl.
- 4. The compound of claim 1, wherein R18 and R19 are hydrogen.
- 5. The compound of claim 432, which is 2-[4-[(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]ethyl]amine and its pharmaceutically acceptable acid addition salts.
- 6. The compound of claim 4, which is 2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-1-piperidinyl]propyl]amine.
- 7. The compound of claim 4, which is 3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-1-piperidinyl]-2-hydroxy-1-propylamine and its pharmaceutically acceptable acid addition salts.
- 8. The compound of claim 1, wherein R18 is hydrogen and R19 is —(C═O)pyridyl.
- 9. The compound of claim 8,A compound which is selected from N-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-3-pyridinecarboxamide and its pharmaceutically acceptable acid addition salts.
- 10. The compound of claim 1, wherein R18 is hydrogen and R19 is
- 11. The compound of claim 1, wherein NR18R19 form aan optionally substituted piperidinyl ring.
- 12. The compound of 1169, which is selected from 1,2-bis-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethane and its pharmaceutically acceptable acid addition salts.
- 13. The compound of claim 1169, which is selected from 1,2-bis-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-hydroxypropane and its pharmaceutically acceptable acid addition salts.
- 14. (S)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropyl methyl carbamate and its pharmaceutically acceptable acid addition salts.
- 15. An antipsychotic composition, which comprises the compound of claim 1 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier.
- 16. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 1.
- 17. An analgesic composition, which comprises the compound of claim 1 in an amount sufficient to produce a pain-relieving effect and a pharmaceutically acceptable carrier.
- 18. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound to claim 1.
- 19. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 1, wherein the compound contains an acylated hydroxy group, or an acylated amino group.
- 20. The depot pharmaceutical composition of claim 819, wherein the hydroxy group is acylated with a (C4-C18)alkanoyl group, or the amino group is acylated with a (C4-C18)alkanoyl group or a (C4-C18)alkoxycarbonyl group.
- 21. The composition of claim 19, which contains a pharmaceutically acceptable oil.
- 22. The composition of claim 21, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 23. The composition of claim 20, which contains a pharmaceutically acceptable oil.
- 24. The composition of claim 23, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 25. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 19 sufficient to produce a long acting antipsychotic effect.
- 26. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 20 sufficient to produce a long acting antipsychotic effect.
- 27. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 24 sufficient to produce a long acting antipsychotic effect.
- 28. A compound of the formula: wherein, X is —O—, —S—, —NH—, or —N(R2)—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl and phenylsulfonyl groups; aryl is as defined hereinafter; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1, except that Y is lower alkoxy, hydroxy or halogen, when p is 2 and X is —O—; in which (R1) is R20, R21 or R22, wherein: R20 is —(CH2)n—, where n is 2, 3, 4 or 5; R21 is —CH2—CH═CH—CH2—, —CH2—C≡C—CH2—, —CH2—CH═CH—CH2—CH2—, —CH2CH2—CH═CH—CH2—, —CH2—C≡C—CH2—CH2—, or —CH2—CH2—C≡C—CH2—, the —CH═CH— bond being cis or trans; R22 is R20 or R21 in which one or more carbon atoms of R20 or R21 are substituted by at least one C1-C6 linear alkyl group, phenyl group or where Z1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2, or halogen, and p is as previously defined; and R18 and R19 are independently selected from the group consisting of: hydrogen, (C1-C12 straight or branched chain)alkyl, —C(═O)—O—(C1-C12)alkyl, —C(═O)—(C1-C12)alkyl, and where NR18R19 taken together form a ring structure selected from the group consisting of piperidinyl, morpholinyl, and piperazinyl; in which aryl is phenyl or wherein R5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; with the proviso that when X is —O— and Y is hydrogen, lower alkyl, lower alkoxy, chlorine, fluorine, bromine, iodine, or a hydroxyl group, R18 and R19 are not lower alkyl; with the proviso that R18 and R19 are not both hydrogen when R1 is —(CH2)2-5—, X is —O—, and Y is 6-F; all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.
- 29. A pharmaceutical composition which comprises a compound of claim 28 and a pharmaceutically acceptable carrier.
- 30. The compound of claim 28, wherein X is —N(R2)—.
- 31. The compound of claim 30, wherein R2 is (C2-C12)alkanoyl.
- 32. The compound of claim 28, wherein R18 and R19 are hydrogen.
- 33. The compound of claim 28, wherein NR18R19 form a piperidinyl ring.
- 34. An antipsychotic composition, which comprises the compound of claim 28 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier.
- 35. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 28.
- 36. An analgesic composition which comprises the compound of claim 28 in an amount sufficient to produce a pain-relieving effect and a pharmaceutically acceptable carrier.
- 37. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 28.
- 38. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the formula: wherein, X is —O—, —S—, —NH—, or —N(R2)—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, alkoxycarbonyl, and phenylsulfonyl groups; aryl is as defined hereinafter; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1, except that Y is lower alkoxy, hydroxy or halogen, when p is 2 and X is —O—; in which (R1) is R20, R21 or R22, wherein: R20 is —(CH2)n—, where n is 2, 3, 4 or 5; R21 is —CH2—CH═CH—CH2—, —CH2—C≡C—CH2—, —CH2—CH═CH—CH2—CH2—, —CH2CH2—CH═CH—CH2—, —CH2—C≡C—CH2—CH2—, or —CH2—CH2—C≡C—CH2—, the —CH═CH— bond being cis or trans; R22 is R20 or R21 in which one or more carbon atoms of R20 or R21 are substituted by at least one C1-C6 linear alkyl group, phenyl group or where Z1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2 or halogen, and p is as previously defined; and R18 and R19 are independently selected from the group consisting of: hydrogen, (C1-C12 straight or branched chain)alkyl, —C(═O)—O—(C1-C12)alkyl, —C(═O)—(C1-C12)alkyl, and where NR18R19 taken together form a ring structure selected from the group consisting of piperidinyl, morpholinyl, and piperazinyl; in which aryl is phenyl or wherein R5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C4-C18)alkanoyl group; in addition, any nitrogen atom may alternatively be acylated with a (C4-C18)alkoxycarbonyl group; and with the proviso that when X is —O— and Y is hydrogen, lower alkyl, lower alkoxy, chlorine, fluorine, bromine, iodine, or a hydroxyl group, R18 and R19 are not lower alkyl; with the proviso that R18 and R19 are not both hydrogen when R1 is —(CH2)2-5—, X is —O—, and Y is 6-F; with the proviso that when R18 and R19 are both hydrogen, R1 is not R20 or R21 when X is —O— and Y is hydrogen; wherein the compound contains an acylated hydroxy group, or an acylated amino group, and further wherein the hydroxy group is acylated with a (C4-C18)alkanoyl group, or the amino group is acylated with a (C4-C18)alkanoyl group or a (C4-C18)alkoxycarbonyl group; all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.
- 39. The composition of claim 38, which contains a pharmaceutically acceptable oil.
- 40. The composition of claim 39, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 41. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 38 sufficient to produce a long acting antipsychotic effect.
- 42. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 40 sufficient to produce a long acting antipsychotic effect.
- 43. A compound of the formula: wherein, X is —O—, —S—, —NH—, or —N(R2)—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, alkoxycarbonyl, and phenylsulfonyl groups; aryl is as defined hereinafter; p is 1 or 2; Y is lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when X is —S—, —NH—, or —N(R2)—; Y is lower alkyl, trifluoromethoxy, nitro, or amino when X is —O—; R1 is —CR24R27—(CR23R24)n—CR24R27— wherein n is 0, 1, 2, or 3; or —CHR24—CH═CH—CHR24—, —CHR24—C≡C—CHR24—, —CHR24—CH═CH—CR23R24—CHR24—, —CHR24—CR23R24—CH═CH—CHR24—, —CHR24—C≡C—CR23R24—CHR24—, or —CHR24—CR23R24—C≡CHR24—, the —CH═CH— bond being cis or trans; R23 is hydrogen, (C1-C18)linear alkyl, phenyl, hydroxy, (C1-C18)alkoxy, aryloxy, aryl(C1-C18)alkyloxy, (C1-C18)alkanoyloxy, hydroxy(C1-C6)alkyl, (C1-C18)alkoxy(C1-C6)alkyl, aryl(C1-C18)alkyloxy(C1-C6)alkyl, (C1-C18)alkanoyloxy(C1-C6)alkyl, or where Z1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2, or halogen, and p is as previously defined; and R24 is hydrogen, (C1-C18)linear alkyl, phenyl, hydroxy(C1-C6)alkyl, (C1-C18)alkoxy(C1-C6)alkyl, phenyl(C1-C6)alkyloxy, aryl(C1-C18)alkyloxy(C1-C6)alkyl, (C1-C18)alkanoyloxy(C1-C6)alkyl, or where Z1 is as previously defined, and p is as previously defined; R27 is hydrogen or R24 and R27 taken together with the carbon to which they are attached form C═O or C═S; and R18 and R19 are independently selected from the group consisting of: hydrogen, (C1-C18 straight or branched chain)alkyl, —C(═O)—O—(C1-C18)alkyl, —C(═O)—(C1-C18)alkyl, —C(═O)-pyridyl, where NR18R19 taken together form a ring structure selected from the group consisting of piperidinyl, morpholinyl, and piperazinyl; where the piperidinyl or piperazinyl ring is optionally substituted by where X, Y, and p are as previously defined; where R4 is hydrogen, lower alkyl, lower alkoxy, hydroxy, tri(C1-C6)alkylsilyloxy, hydroxy lower alkyl, alkanoyloxy lower alkyl, amino, mono- or dialkylamino, (C1-C18)acyl amino, (C1-C18)alkanoyl, trifluoromethyl, chlorine, fluorine, bromine, —O—C(═O)—(C1-C18 straight or branched chain)alkyl or —C(═O)-aryl; where R28 is hydrogen, (C1-C6) alkyl, aryl(C1-C6) alkyl, phenyl, or substituted phenyl; in which aryl is phenyl or wherein R5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C4-C18)alkanoyl group; in addition, any nitrogen atom may alternatively be acylated with a (C4-C18)alkoxycarbonyl group; and m is 1, 2, or 3; with the proviso that when X is —O— and Y is hydrogen, lower alkyl, lower alkoxy, chlorine, fluorine, bromine, iodine, or a hydroxyl group, R18 and R19 are not lower alkyl; with the proviso that R18 and R19 are not hydrogen when R1 is —(CH2)2-5—, X is —O—, and Y is 6-F; all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.
- 44. The compound of claim 43, wherein X is —N(R2)—.
- 45. The compound of claim 44, wherein R2 is (C2-C18)alkanoyl or (C1-C18)alkoxycarbonyl.
- 46. The compound of claim 43, wherein R18 and R19 are hydrogen.
- 47. The compound of claim 43, wherein R18 is hydrogen and R19 is —(C═O)-pyridyl.
- 48. The compound of claim 43, wherein R18 is hydrogen and R19 is
- 49. The compound of claim 43, wherein NR18R19 form an optionally substituted piperidinyl ring.
- 50. An antipsychotic composition, which comprises the compound of claim 43 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier.
- 51. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 43.
- 52. An analgesic composition, which comprises the compound of claim 43 in an amount sufficient to produce an pain-relieving effect and a pharmaceutically acceptable carrier.
- 53. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 43.
- 54. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 43, wherein the compound contains an acylated hydroxy group, or an acylated amino group.
- 55. The depot pharmaceutical composition of claim 54, wherein the hydroxy group is acylated with a (C4-C18)alkanoyl group, or the amino group is acylated with a (C4-C18)alkanoyl group or a l (C4-C18)alkoxycarbonyl group.
- 56. The composition of claim 34, which contains a pharmaceutically acceptable oil.
- 57. The composition of claim 56, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 58. The composition of claim 55, which contains a pharmaceutically acceptable oil.
- 59. The composition of claim 58, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 60. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 54 sufficient to produce a long acting antipsychotic effect.
- 61. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 55 sufficient to produce a long acting antipsychotic effect.
- 62. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 59 sufficient to produce a long acting antipsychotic effect.
- 63. A compound of the formula: wherein, X is —O—, —S—, —NH—, or —N(R2)—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl and phenylsulfonyl groups; aryl is as defined hereinafter; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1, except that Y is lower alkoxy, hydroxy or halogen, when p is 2 and X is —O—; in which (R1) is R20, R21 or R22, wherein: R20 is —(CH2)n—, where n is 2, 3, 4 or 5; R21 is —CH2—CH═CH—CH2—, —CH2—C≡C—CH2—, —CH2—CH═CH—CH2—CH2—, —CH2CH2—CH═CH—CH2—, —CH2—C≡C—CH2—CH2—, or —CH2—CH2—C≡C—CH2—, the —CH═CH— bond being cis or trans; R22 is R20 or R21 in which one or more carbon atoms of R20 or R21 are substituted by at least one C1-C6 linear alkyl group, phenyl group or where Z1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2 or halogen, and p is as previously defined; and R18 and R19 are independently selected from the group consisting of: (C13-C18 straight or branched chain)alkyl, —C(═O)—O—(C13-C18)alkyl, —C(═O)—(C13-C18)alkyl, and —C(═O)-pyridyl, where NR18R19 taken together form a ring structure selected from the group consisting of piperidinyl, morpholinyl, and piperazinyl; where the piperidinyl or piperazinyl ring is substituted by where X, Y, and p are as previously defined; where tri(C1-C6)alkylsilyloxy, hydroxy lower alkyl, alkanoyloxy lower alkyl, amino, mono- or dialkylamino, (C1-C18)acyl amino, (C1-C18)alkanoyl, trifluoromethyl, chlorine, fluorine, bromine, —O—C(═O)—(C1-C18 straight or branched chain)alkyl or —C(═O)-aryl; where R28 is hydrogen, (C1-C6) alkyl, aryl(C1-C6) alkyl, phenyl, or substituted phenyl; in which aryl is phenyl or wherein R5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C4-C18)alkanoyl group; in addition, any nitrogen atom may alternatively be acylated with a (C4-C18)alkoxycarbonyl group; and m is 1, 2, or 3; all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.
- 64. A pharmaceutical composition which comprises a compound of claim 63 and a pharmaceutically acceptable carrier therefor.
- 65. The compound of claim 63, wherein X is —N(R2)—.
- 66. The compound of claim 63, wherein at least one of R18 and R19 is —(C═O)-pyridyl.
- 67. The compound of claim 63, wherein R18 is hydrogen and R19 is
- 68. The compound of claim 63, wherein NR18R19 form a substituted piperidinyl ring.
- 69. An antipsychotic composition, which comprises the compound of claim 63 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier.
- 70. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 63.
- 71. An analgesic composition, which comprises the compound of claim 63 in an amount sufficient to produce a pain-relieving effect and a pharmaceutically acceptable carrier.
- 72. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound to claim 63.
- 73. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 63.
- 74. The depot pharmaceutical composition of claim 73, wherein the hydroxy group is acylated with a (C4-C18)alkanoyl group, or the amino group is acylated with a (C4-C18)alkanoyl group or a (C4-C18)alkoxycarbonyl group.
- 75. The composition of claim 73, which contains a pharmaceutically acceptable oil.
- 76. The composition of claim 75, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 77. The composition of claim 74, which contains a pharmaceutically acceptable oil.
- 78. The composition of claim 77, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 79. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 73 sufficient to produce a long acting antipsychotic effect.
- 80. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 74 sufficient to produce a long acting antipsychotic effect.
- 81. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 78 sufficient to produce a long acting antipsychotic effect.
CROSS-REFERENCE TO RELATED APPLICATION
This is a division of pending application Ser. No. 08/329,000 filed Oct. 25, 1994 of Joseph T. Strupczewski, Grover C. Helsley, Edward J. Glamkowski, Yulin Chiang, Kenneth J. Bordeau, Peter A. Nemoto and John J. Tegeler for HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS, now U.S. Pat. No. 5,776,963, which is a CIP application of Ser. No. 08/144,265, filed Oct. 28, 1993, now abaondoned, which is a CIP application of Ser. No. 07/969,383, filed Oct. 30, 1992, now U.S. Pat. No. 5,364,866, which is a CIP application of Ser. No. 07/788,269, filed Nov. 5, 1991, now abandoned, which is a CIP application of Ser. No. 07/944,705, filed Sep. 5,1991, now abandoned, which is a continuation application of Ser. No. 07/619,825, filed Nov. 29, 1990, now abandoned, which is a continuation application of Ser. No. 07/456,790, filed Dec. 29, 1989, now abandoned, which is a CIP application of Ser. No. 07/354,411, filed May 19, 1989, now abandoned.
US Referenced Citations (14)
Foreign Referenced Citations (23)
Number |
Date |
Country |
353 0089 |
Mar 1986 |
DE |
2 503 816 |
Jul 1975 |
DK |
0 013 612 |
Jul 1980 |
EP |
0 135 781 |
Apr 1985 |
EP |
0 196 096 |
Oct 1986 |
EP |
0 261 688 |
Mar 1988 |
EP |
0 302 423 |
Feb 1989 |
EP |
0 314 098 |
May 1989 |
EP |
0 329 168 |
Aug 1989 |
EP |
0 353 821 |
Feb 1990 |
EP |
0 357 134 |
Mar 1990 |
EP |
0 398 425 |
Nov 1990 |
EP |
0 402 644 |
Dec 1990 |
EP |
0 464 846 |
Jan 1992 |
EP |
0 542 136 |
May 1993 |
EP |
2 63 432 |
Feb 1986 |
GB |
233 710 |
May 1990 |
NZ |
233 503 |
Jun 1991 |
NZ |
233 525 |
Sep 1991 |
NZ |
WO 9316703 |
Aug 1985 |
WO |
PCT WO9309102 |
May 1993 |
WO |
PCT WO9316073 |
Aug 1993 |
WO |
PCT WO9418196 |
Aug 1994 |
WO |
Non-Patent Literature Citations (1)
Entry |
Fuller, R.W., Drugs Acting on Serotonergic Neuronal Systems, Biology of Serotonergic Transmission, John Wiley & Sons Ltd., 1982, pp. 221-247. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
08/469357 |
Jun 1995 |
US |
Child |
09/240842 |
|
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
07/619825 |
Nov 1990 |
US |
Child |
07/944705 |
|
US |
Parent |
07/456790 |
Dec 1989 |
US |
Child |
07/619825 |
|
US |
Continuation in Parts (5)
|
Number |
Date |
Country |
Parent |
08/144265 |
Oct 1993 |
US |
Child |
08/329000 |
|
US |
Parent |
07/969383 |
Oct 1992 |
US |
Child |
08/144265 |
|
US |
Parent |
07/788269 |
Nov 1991 |
US |
Child |
07/969383 |
|
US |
Parent |
07/944705 |
Sep 1991 |
US |
Child |
07/788269 |
|
US |
Parent |
07/354411 |
May 1989 |
US |
Child |
07/456790 |
|
US |
Reissues (1)
|
Number |
Date |
Country |
Parent |
08/469357 |
Jun 1995 |
US |
Child |
09/240842 |
|
US |